The Federal Reserve’s new leader had her “irrational exuberance” moment in her most recent congressional testimony. #-ad_banner-#Boy, am I glad she got that out of the way. Janet Yellen’s predecessor Alan Greenspan uttered those two words back in 1996, and like him, Yellen seemed to be trying to jawbone stock prices down before they form a bubble and scuttle central bank policy. In 1996 after Greenspan’s remarks, stocks went into a temporary tailspin the next morning — yet an investor who ignored his advance and bought into the S&P 500 a day later has earned a 268% return… Read More
The Federal Reserve’s new leader had her “irrational exuberance” moment in her most recent congressional testimony. #-ad_banner-#Boy, am I glad she got that out of the way. Janet Yellen’s predecessor Alan Greenspan uttered those two words back in 1996, and like him, Yellen seemed to be trying to jawbone stock prices down before they form a bubble and scuttle central bank policy. In 1996 after Greenspan’s remarks, stocks went into a temporary tailspin the next morning — yet an investor who ignored his advance and bought into the S&P 500 a day later has earned a 268% return since then. Likewise, Yellen probably created a big opportunity this month when she trashed biotech and social media stocks in general, saying they have “overstretched valuations.” Stocks sold off on her remarks. The problem with a statement that lumps together all the stocks in a sector is that you end up throwing out some gems along with the high-flying duds. I’m not sure about social media stocks, but I do know there are at least three biotech stocks out there with the kind of hyperbolic growth and profit potential that justifies their rising share prices. Three biotech stocks that should… Read More